Physician profile
Lanaya W Smith
NPI 1669632899
$2,316.18
in general payments reported to CMS, 2019-2025
16 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,611 · 2020: $39.21 · 2021: $57.16 · 2022: $196 · 2023: $198 · 2024: $87.55 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $413.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $412.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $584.40 | 2019-2024 | |
| Abbvie INC. | $379.69 | 2019-2025 | Rinvoq |
| Novartis Pharmaceuticals Corporation | $257.82 | 2019-2025 | |
| Amgen INC. | $216.75 | 2019-2025 | Evenity, Tavneos |
| Janssen Biotech, INC. | $162.74 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $139.52 | 2019 | |
| Glaxosmithkline, LLC. | $115.43 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $98.76 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $98.14 | 2019-2020 | |
| Ucb, INC. | $71.91 | 2019 | |
| Pacira Therapeutics, INC. | $52.28 | 2019 | |
| Hikma Pharmaceuticals USA | $50.13 | 2019 | |
| Lilly USA, LLC | $35.60 | 2019 | |
| Antares Pharma, INC. | $21.31 | 2019 | |
| Radius Health, INC. | $16.70 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $15.00 | 2023 | Lupkynis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lanaya Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.